You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

  • Authors: Frederick R. Appelbaum, MD; Stephen J. Forman, MD; Gail J. Roboz, MD; David Steensma, MD; Willis Navarro, MD
  • CME Released: 5/21/2013; Reviewed and Renewed: 9/23/2014
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 9/23/2015, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

The goal of this activity is to discuss the latest approaches to the treatment of older patients with MDS and AML.

Upon completion of this activity, participants will be able to:

  1. Identify disease- and patient-related factors that predict outcomes of hematopoietic cell transplantation (HCT), new drugs, or combination therapy in older patients with MDS and AML
  2. Explain recent clinical trial results that have influenced the selection of patients for treatment of MDS and AML
  3. Compare the risks and benefits of treatment options and how timing of therapy choices affects outcomes
  4. Describe appropriate candidates for a prospective study on outcomes of HCT in adults 65 years of age and older with MDS


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Frederick R. Appelbaum, MD

    Executive Director, Seattle Cancer Care Alliance; Director, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine, Seattle, Washington

    Disclosures

    Disclosure: Frederick R. Appelbam, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Celator Pharmaceuticals, Inc.; Pfizer Inc; Igenica, Inc.; Abbott Laboratories

    Dr Appelbaum does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Appelbaum does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Stephen J. Forman, MD

    Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation; Clinical Director, Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, California

    Disclosures

    Disclosure: Stephen J. Forman, MD, has disclosed no relevant financial relationships.

    Dr Forman does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Forman does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Gail J. Roboz, MD

    Director, Leukemia Program; Associate Professor of Medicine, Weill Medical College, Cornell University, New York, New York

    Disclosures

    Disclosure: Gail J. Roboz, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Celgene Corporation

    Dr Roboz does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Roboz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • David Steensma, MD

    Associate Professor of Medicine, Harvard Medical School; Adult Leukemia Program, Dana-Farber Cancer Institute; Hematological Oncology Service, Brigham & Women’s Hospital, Boston, Massachusetts

    Disclosures

    Disclosure: David Steensma, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Genoptix, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Amgen Inc.

    Dr Steensma does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Steensma does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States

  • Willis Navarro, MD

    Vice President, Transplant Medical Services, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Current position: Vice President of Clinical Research and Development at Atara Biotherapeutics and Associate Clinical Professor of Medicine at the University of California, San Francisco

    Disclosures

    Disclosure: Willis Navarro, MD, has disclosed no relevant financial relationships.

    Dr Navarro does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Navarro does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

  • Charlotte Warren

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

  • Ellyce Hayes

    Strategic Marketing Specialist, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Disclosures

    Disclosure: Ellyce Hayes has disclosed no relevant financial relationships.

  • Alissa Salvato

    Medical Education Outreach Specialist, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Disclosures

    Disclosure: Alissa Salvato has disclosed no relevant financial relationships.

  • Tim Walker

    Medical Writer, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Disclosures

    Disclosure: Tim Walker has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Authors: Frederick R. Appelbaum, MD; Stephen J. Forman, MD; Gail J. Roboz, MD; David Steensma, MD; Willis Navarro, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 5/21/2013; Reviewed and Renewed: 9/23/2014

Valid for credit through: 9/23/2015, 11:59 PM EST

processing....

Abbreviations

AA = aplastic anemia
ALL = acute lymphoblastic leukemia
ALLIANCE trial = Alliance for Clinical Trials in Oncology
AML = acute myeloid leukemia
ASH = American Society of Hematology
ATG = antithymocyte globulin
ATRA = all-trans-retinoic acid
CALGB = Cancer and Leukemia Group B
CBF = core-binding factor
CEBPA = CCAAT/enhancer binding protein-alpha
CIBMTR = Center for International Blood and Marrow Transplant Research
CMML = chronic myelomonocytic leukemia
CR = complete remission
CRBN = cereblon
DA = daunorubicin + cytarabine
DACi = deacetylase activity inhibitor
AGO = daunorubicin + cytarabine + gemtuzumab
DNMT3A = DNA methyltransferase 3A
DNR = daunorubicin
DFS = disease-free survival
ECOG = European Cooperative Oncology Group
EFS = event-free survival
ESA = erythropoiesis-stimulating agent
FDA = US Food and Drug Administration
G-CSF = granulocyte-colony stimulating factor
FHCRC = Fred Hutchinson Cancer Research Center
FLT3 = FMS-like tyrosine kinase 3
GVHD = graft-versus-host disease
HCT = hematopoietic cell transplantation
HCT-CI = hematopoietic cell transplantation comorbidity index
HLA = human leukocyte antigen
HMA = hypomethylating agent
IL-3 = interleukin 3
IMiDs = immunomodulatory derivatives
IPSS = International Prognostic Scoring System
JAK-2 = Janus tyrosine kinase 2
JCO = Journal of Clinical Oncology
LD = low-dose
LDAC = low-dose cytosine arabinoside (Ara-C)
LGL = large granular lymphocyte
MAP kinase = mitogen-activated protein kinase
MCV = mean corpuscular volume
MDA = MD Anderson Cancer Center
MDACC = MD Anderson Cancer Cancer
MDS = myelodysplastic syndromes
MPD = myeloproliferative disease
MRC = Medical Research Council
MRD = minimal residual disease
NCCN = National Comprehensive Cancer Network
NIH = National Institutes of Health
NK cells = natural killer cells
NMDP = National Marrow Donor Program®
ORR = overall response rate
OS = overall survival
PRCA = pure red cell aplasia
RARS = refractory anemia with ring sideroblasts
RBC = red blood cell
RFS = relapse-free survival
RIC = reduced-intensity conditioning (regimen)
SC = supportive care
SWOG = formerly the Southwest Oncology Group
TET2 = Ten-Eleven-Translocation-2
TNFα = tumor necrosis factor alpha
TRM = transplant-related mortality (risk score)
VEGF = vascular endothelial growth factor
WBC = white blood cell count
WHO = World Health Organization
WPSS = WHO classification-based Prognostic Scoring System

« Return to: Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
  • Print